Brainsway initiates clinical evaluation of rotational field ‘Deep TMS 360’

BrainsWay announced that it will be clinically evaluating an innovative stimulation technology in two new feasibility trials. The studies both involve BrainsWay’s exclusive, patented “Rotational Field” TMS which employs a method of stimulation that enables activation of a greater number of neurons in the brain. The Company aims to assess the potential clinical impact of this technology on patients in two newly launched feasibility studies. One study will test the safety and efficacy of this technology in the field of rehabilitation following stroke, a devastating neurological condition. Another study will test the technology in the field of obsessive-compulsive disorder utilizing an accelerated protocol. “We are proud to continue to be at the forefront of innovation in the field of noninvasive brain stimulation,” said Hadar Levy, Chief Executive Officer of BrainsWay. “We believe that our Rotational Field technology holds significant potential to change the current TMS paradigm. We look forward to testing its capabilities in these newly launched post-stroke rehabilitation and OCD feasibility studies.”